FDA begins process that will end the use of bevacizumab (Avastin®) for metastatic breast cancer.

The Food and Drug Administration (FDA) has begun the process of withdrawing the approval of bevacizumab (Avastin®) for the treatment of breast cancer.  The agency states that the benefits of Avastin® do not outweigh the risks for this cancer type.